COMP <GO>
QGEN vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Qiagen N.V. (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: QGEN 6
— LLY 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $50.22 (-0.24%) • MKT CAP: $10.37B
balance-sheet
3.54
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (QGEN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | QGEN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.20% | 83.64% | -21.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.00% | 32.36% | -24.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 17.6x | 36.4x | -18.82 | QGEN | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 2.30% | +2.07 | QGEN | /fcf-yield <GO> |
| Operating Margin | 22.30% | 40.21% | -17.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | 20.30% | 31.90% | -11.60 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 45.51% | -39.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.52% | 0.49% | +0.03 | QGEN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.54 | 9.29 | -5.75 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 9/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.77% | -0.07 | QGEN | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 71.9 | 77.9 | -5.95 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.51 | +0.44 | QGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.7x | 26.3x | -3.55 | QGEN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.37B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | QGEN REV | LLY REV | QGEN GROSS % | LLY GROSS % | QGEN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.09B | $65.18B | 62.2% | 83.0% | $453.3M | $16.81B |
| FY 2024 | $1.98B | $45.04B | 48.9% | 81.3% | $506.4M | $8.82B |
| FY 2023 | $1.97B | $34.12B | 44.0% | 79.3% | $371.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
QGEN // BETA 0.95
LLY // BETA 0.51